Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Baricitinib in Pediatric Patients Hospitalized with COVID-19
2021-001338-21Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of baricitinib in coronavirus disease 2019 (COVID-19), sponsored by Eli Lilly and Company. Primary endpoint: Pharmacokinetic parameters (AUC, Cmax) of baricitinib. Started Aug 2021; status: active.
02
Drugs
baricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-001338-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001338-21.